GlaxoSmithKline PLC
LSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
LSE:GSK
Watchlist
Price: 1 341.5 GBX 0.26% Market Closed
Market Cap: 54.7B GBX
Have any thoughts about
GlaxoSmithKline PLC?
Write Note

GlaxoSmithKline PLC
Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

GlaxoSmithKline PLC
Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
GlaxoSmithKline PLC
LSE:GSK
Minority Interest
-ÂŁ602m
CAGR 3-Years
N/A
CAGR 5-Years
1%
CAGR 10-Years
N/A
AstraZeneca PLC
LSE:AZN
Minority Interest
$86m
CAGR 3-Years
72%
CAGR 5-Years
-44%
CAGR 10-Years
14%
Verona Pharma PLC
NASDAQ:VRNA
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Minority Interest
$14m
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
-2%
Dechra Pharmaceuticals PLC
LSE:DPH
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GlaxoSmithKline PLC
Glance View

Market Cap
54.7B GBX
Industry
Pharmaceuticals

GlaxoSmithKline PLC (GSK) is a global healthcare giant rooted in extensive research and development, dedicated to improving the health and well-being of people around the world. Founded in 2000 through a merger of Glaxo Wellcome and SmithKline Beecham, GSK has built a diverse portfolio that spans pharmaceuticals, vaccines, and consumer healthcare. With a strong emphasis on innovation, GSK invests heavily in R&D, focusing on tackling significant health challenges such as infectious diseases, oncology, and respiratory ailments. The company’s robust pipeline showcases its commitment to advancing medical science, promising both potential breakthroughs for patients and lucrative prospects for investors. In recent years, GSK has taken strategic steps to simplify its business model, including the spin-off of its consumer healthcare segment into a separate entity. This maneuver has allowed GSK to concentrate on its core pharmaceutical and vaccine operations, optimizing its resources towards high-growth areas. As the world faces ongoing health crises and the demand for vaccines, particularly following the COVID-19 pandemic, GSK is well-positioned to capitalize on its innovation and solid market presence. For investors, GSK's balance sheet reflects a stable dividend, attractive growth prospects, and a commitment to sustainable practices, fostering confidence that it remains a compelling choice in the ever-evolving healthcare landscape.

GSK Intrinsic Value
2 384.41 GBX
Undervaluation 44%
Intrinsic Value
Price

See Also

What is GlaxoSmithKline PLC's Minority Interest?
Minority Interest
-602m GBP

Based on the financial report for Jun 30, 2024, GlaxoSmithKline PLC's Minority Interest amounts to -602m GBP.

What is GlaxoSmithKline PLC's Minority Interest growth rate?
Minority Interest CAGR 5Y
1%

Over the last year, the Minority Interest growth was -13%.

Back to Top